Impact of Data Integrity Audits on Pharma Microbial QC Labs

Most people are aware of the requirements of the code of federal regulations 21 CFR Part 11 for computer software security, which have been a major pharmaceutical IT focus for approximately 10 years.

However, within the 21 CFR 11 requirements lurked another high-risk component: “Data Integrity”. Simply put, Data Integrity (“DI”) is the assurance that data records are accurate, complete, intact and maintained within their original context so as to make the data trustworthy.

In pharmaceutical QC labs, there are often many manual steps in the performance of a routine QC analytic test to release a product (Figure 1). High risk areas were associated with the amount of human input required and how closely that input was monitored and verified.

Plus d'information ici.

Posts les plus consultés de ce blog

On déménage...

USA : un site destiné à gérer la distribution des vaccins contre la Covid-19 de 44 millions $ construit par Deloitte abandonné à cause des bogues informatiques